Nuvectis Pharma, Inc.
NVCT
$9.44
-$0.05-0.53%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -50.45% | 6.21% | -6.16% | 37.01% | -12.60% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1.55% | -8.16% | -2.62% | 6.23% | 7.68% |
| Change in Net Operating Assets | 347.80% | 304.11% | 109.84% | -195.55% | 3.19% |
| Cash from Operations | -2.54% | 20.40% | 30.70% | -13.19% | -18.68% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 162.31% | -12.74% | -64.38% | 438.18% | -20.96% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -148.00% | 9.09% | 64.05% | -1,056.25% | 103.66% |
| Cash from Financing | 162.80% | -12.86% | -64.40% | 412.10% | 30.44% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 244.03% | 29.75% | -498.82% | 111.52% | -15.43% |
